We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Activiomics Announces Appointment of Non-Executive Chairman
News

Activiomics Announces Appointment of Non-Executive Chairman

Activiomics Announces Appointment of Non-Executive Chairman
News

Activiomics Announces Appointment of Non-Executive Chairman

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Activiomics Announces Appointment of Non-Executive Chairman"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Activiomics Limited. has announced the appointment of industry leader Dr Trevor Nicholls to its Board as Non-Executive Chairman.

Dr Nicholls has over 30 years’ experience of building international businesses in the life science industry.

Currently he is CEO of CABI, a not-for-profit inter-governmental organization owned by 46 member countries worldwide and is Non-Executive Chairman of Oxford Nanopore Technologies, which is developing the GridION system, a new generation of electronic molecular analysis system for use in scientific research, personalized medicine, crop science, and security/defence.

His previous board roles include Chief Commercial Officer of Affymetrix Inc, based in California and, prior to that, CEO of Oxagen, a UK biotech company where he raised £50m over three venture-backed financing rounds and secured major commercial partnerships and academic collaborations.

Welcoming Dr Nicholls to the board, Dr Mark Warne, CEO of Activiomics, said: “I am confident that Trevor’s broad background in leading companies as they develop commercially will be invaluable to Activiomics as we move to the next phase of our development. He brings both a depth of international experience in commercial markets as well as a proven ability in raising finance for early-stage companies.”

Activiomics has developed innovative technologies using mass spectrometry to interrogate and interpret the activity of whole cell signalling pathways.

This technology is well-positioned to support personalized medicine initiatives, which are influencing increasing numbers of therapeutic programs.

The Company has recently met internal milestones resulting in a second tranche of funding from IP Group plc, (LSE: ipo) ("IP Group"), the developer of intellectual property based businesses. This follows an initial investment by IP Group in 2011.

Commenting on his appointment, Dr Nicholls said: “The unique nature of Activiomics’ approach to identifying robust biomarkers has already been validated by a number of partnerships with large pharmas, including with GlaxoSmithKline, UCB and Genentech, and the Company is well placed to take advantage of the rapidly growing personalized medicine market. I am delighted to be joining the Board at a time when it has received a financing injection on the back of this success and look forward to helping the company in its next stage of development.”

Advertisement